Kimal PLC is delighted to announce its new strategic partnership with Marizyme, Inc. for DuraGraft®, the Company’s flagship product.
DuraGraft is an intraoperative vascular graft storage and flushing solution that prevents ischaemia reperfusion injury, which is the basis for vein graft disease; and Kimal will have exclusive distribution rights in the UK.
Matt Press, Kimal CEO, says, “We are delighted to announce our partnership with Marizyme to launch DuraGraft in the UK. Kimal’s Vision is to provide treatment solutions that support best-in-class patient outcomes, and we believe that DuraGraft represents the best elements of this Vision. We therefore are extremely excited about bringing this innovative technology to coronary artery bypass graft procedures in the UK, and specifically launching a product that improves the outcomes for those patients undergoing this life-saving procedure.”
To learn more, please contact marcomms@kimal.co.uk